Insulet Co. (PODD) EVP Aiman Abdel-Malek Sells 27,349 Shares
Insulet Co. (NASDAQ:PODD) EVP Aiman Abdel-Malek sold 27,349 shares of the stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $94.03, for a total value of $2,571,626.47. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Aiman Abdel-Malek also recently made the following trade(s):
- On Friday, March 1st, Aiman Abdel-Malek sold 1,608 shares of Insulet stock. The stock was sold at an average price of $95.22, for a total value of $153,113.76.
Shares of PODD stock opened at $98.04 on Friday. Insulet Co. has a fifty-two week low of $70.80 and a fifty-two week high of $108.90. The stock has a market cap of $5.68 billion, a P/E ratio of 1,960.80 and a beta of 1.60. The company has a quick ratio of 3.37, a current ratio of 3.99 and a debt-to-equity ratio of 2.79.
Hedge funds have recently made changes to their positions in the stock. PRW Wealth Management LLC bought a new position in Insulet during the fourth quarter valued at about $40,000. Cutler Group LP bought a new position in Insulet during the fourth quarter valued at about $126,000. Nordea Investment Management AB bought a new position in Insulet during the fourth quarter valued at about $159,000. Parallel Advisors LLC boosted its stake in Insulet by 198.7% during the fourth quarter. Parallel Advisors LLC now owns 2,240 shares of the medical instruments supplier’s stock valued at $177,000 after buying an additional 1,490 shares in the last quarter. Finally, Stephens Inc. AR bought a new position in Insulet during the fourth quarter valued at about $183,000.
Several research analysts have recently issued reports on the company. Oppenheimer set a $100.00 price target on Insulet and gave the stock a “hold” rating in a research note on Tuesday, February 26th. Northland Securities reissued a “buy” rating and issued a $100.00 price target on shares of Insulet in a research note on Tuesday, February 26th. BidaskClub cut Insulet from a “buy” rating to a “hold” rating in a research note on Friday, February 22nd. Canaccord Genuity increased their price target on Insulet from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Tuesday, February 19th. Finally, ValuEngine cut Insulet from a “strong-buy” rating to a “buy” rating in a research note on Monday, January 7th. Four research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $103.08.
TRADEMARK VIOLATION NOTICE: This report was first posted by Watch List News and is owned by of Watch List News. If you are reading this report on another site, it was stolen and republished in violation of US & international trademark & copyright law. The original version of this report can be accessed at https://www.watchlistnews.com/insulet-co-podd-evp-aiman-abdel-malek-sells-27349-shares/2896310.html.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device.
Featured Article: Price to Earnings Ratio (PE), For Valuing Stocks
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.